Expanded Access Program To Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib

Sponsor:

Revolution Medicines

Sponsor Study ID:

RMC-6236-401 EAP

CTO #:

104390

NCT Number:

Phase:

N/A

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Pancreas

Study Objectives:

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)

---

Request more information